| Schedule of the items included within net loss regularly provided to the CODM |
| | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Revenue | $ | 19,291 | | $ | 20,197 | | $ | 38,350 | | $ | 38,717 | Cost of revenue (excluding amortization of intangible assets) | | 5,253 | | | 5,997 | | | 11,697 | | | 11,910 | Amortization of intangible assets | | 95 | | | 95 | | | 190 | | | 190 | Gross profit | | 13,943 | | | 14,105 | | | 26,463 | | | 26,617 | Sales and marketing: | | | | | | | | | | | | Sales and sales management | | 10,165 | | | 11,216 | | | 20,961 | | | 22,830 | International | | 2,062 | | | 1,451 | | | 4,021 | | | 2,808 | Other sales and marketing (a) | | 4,215 | | | 4,190 | | | 7,997 | | | 7,827 | Total sales and marketing | | 16,442 | | | 16,857 | | | 32,979 | | | 33,465 | General and Administrative: | | | | | | | | | | | | Finance and Legal | | 1,996 | | | 1,968 | | | 4,022 | | | 3,919 | Other general and administrative (b) | | 2,065 | | | 2,158 | | | 4,205 | | | 4,043 | Total general and administrative | | 4,061 | | | 4,126 | | | 8,227 | | | 7,962 | Research and Development: | | | | | | | | | | | | Clinical | | 1,164 | | | 872 | | | 2,223 | | | 1,780 | Regulatory and quality | | 547 | | | 427 | | | 1,087 | | | 867 | Other research and development (c) | | 1,012 | | | 904 | | | 1,756 | | | 2,096 | Total research and development | | 2,723 | | | 2,203 | | | 5,066 | | | 4,743 | Other segment items (d) | | (1,979) | | | (842) | | | (3,726) | | | (1,634) | Net loss | $ | (11,262) | | $ | (9,923) | | $ | (23,535) | | $ | (21,187) | | | | | | | | | | | | | (a) Other sales and marketing includes strategy, analytics and allocated facility expenses. | (b) Other general and administrative includes executive, human resources, information technology and allocated facility expenses. | (c) Other research and development includes engineering and allocated facility expenses. | (d) Other segment items include other operating income and other expenses as disclosed in the consolidated statements of operations and comprehensive loss; interest expense, loss on extinguishment of debt, other income and income tax expense. |
|
| Schedule of Disaggregation of Revenue |
The following table presents revenue disaggregated by the Company’s portfolio of products (in thousands): | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | OviTex | | $ | 13,308 | | $ | 12,487 | | $ | 25,927 | | $ | 24,596 | OviTex PRS | | | 5,460 | | | 7,333 | | | 11,341 | | | 13,377 | Other | | | 523 | | | 377 | | | 1,082 | | | 744 | Total revenue | | $ | 19,291 | | $ | 20,197 | | $ | 38,350 | | $ | 38,717 |
|
| Schedule of dilutive securities excluded |
| | | | | | | Six months ended June 30, | | | 2026 | | 2025 | Stock options | | 3,485,351 | | 2,817,979 | Unvested restricted stock units | | 2,015,615 | | 1,359,116 | Common stock warrants | | 88,556 | | 88,556 | Common stock warrants issued with credit agreement | | 2,000,000 | | — | Total | | 7,589,522 | | 4,265,651 |
|